Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019422 · ClinicalTrials.gov registry record · Phase 2
Lobradimil and Carboplatin in Treating Children With Brain Tumors
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019422: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019422 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019422, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of carboplatin and lobradimil in treating children with brain tumors that have not responded to previous treatment.
Interventions
- DRUG carboplatin
- DRUG lobradimil
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-03 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
What the finished NCT00019422 record still lists
NCT00019422 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT00019422 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019422 about?
NCT00019422 is a clinical study titled "Lobradimil and Carboplatin in Treating Children With Brain Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of carboplati...
What is the current status of trial NCT00019422?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-03. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00019422?
The interventions under investigation include: carboplatin (DRUG), lobradimil (DRUG).
Who is sponsoring clinical trial NCT00019422?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia